WHO R&D Blueprint COVID-19
At present, there are no vaccines, no curative treatments and a strong need for more rapid diagnostic tests for COVID-19. Therefore, research is needed to accelerate timely, adequate, affordable and equitable access to these products. Switzerland supports WHO efforts to elaborate a research roadmap based on knowledge gaps for COVID-19 pandemic treatments, vaccines and related epidemiological studies, with a focus on low- and middle income countries.
Renforcement des systèmes de santé
- Organisation mondiale de la santé
With the announcement by WHO on 30.01.2020 that the novel coronavirus constituted a Public Health Emergency of International Concern, a Research and Development (R&D) program for COVID-19 was activated (“WHO R&D Blueprint”).
On 11-12.02.2020, WHO convened a Global Research Summit where 500+ scientists identified critical research priorities. A coordinated Global Research and Innovation Roadmap was then developed. This proposal is aligned with the priorities of this Roadmap, with a focus on treatments, vaccines and related epidemiological studies.
The research roadmap with its clear priority setting in research on diagnostics, therapies and vaccines against COVID-19 is essential for Switzerland which formally participates to the trials. This support is also complementary to Switzerland’s contribution to the Coalition for Epidemic Preparedness Innovations (CEPI).
|Objectifs||Accelerate research for timely, adequate, affordable and equitable access to any innovation and medical countermeasures to those at risk of COVID-19, with a focus on LMICs.|
Researchers and clinicians in LMICs.
The global research and development community for COVID-19.
Key funders and implementing partners including GAVI, CEPI, Wellcome Trust.
Manufacturers, regulators and procurement agencies (UNICEF, Global Fund, etc.).
Patients and population at high risk for COVID-19.
|Effets à moyen terme||
· Therapeutics Solidarity Trial have identified treatments that lead to a reduction in all-cause mortality and a reduction in the duration of hospital stay.
· Vaccine Solidarity Trials have identified candidate vaccines for licensure and equitable access to those at highest risk.
- Solidarity epidemiological studies have generated evidence on risk factors for transmission; impact of infection prevention and control measures in health care settings; incidence of infection, viral persistence on surfaces, etc.
 The Solidarity Trial is an international clinical trial to help find an effective treatment for COVID-19, launched by WHO and partners. It is hoped that one or more of the treatments under trial will result in improving clinical outcomes in COVID-19 patients and save lives.
Principaux résultats attendus:
· LMICs have participated in Solidarity trial
· Collaborators in LMICs have participated
- Collaborators in LMICs have joined Solidarity
Principaux résultats antérieurs: Not applicable. This is a new proposal.
|Direction/office fédéral responsable||
Coopération au développement
|Partenaire de projet||
Organisme des Nations Unies (ONU)
Governments, NGOs, private sector
|Coordination avec d'autres projets et acteurs||GAVI, COVAX AMC and COVAX Facility, CEPI, FIND|
|Budget||Phase en cours Budget de la Suisse CHF 2'000'000 Budget suisse déjà attribué CHF 2'000'000 Budget y compris partenaires de projet CHF 15'586'577|